Harmony Biosciences Taps Peter Anastasiou as CEO, Reaffirms $1B+ 2026 Outlook
HRMY sits 50% above its 52-week low of $25.52.
Summary
Harmony Biosciences announced a planned CEO succession: COO Peter Anastasiou becomes President and CEO on January 1, 2027, succeeding Jeffrey Dayno, who retires December 31, 2026. Full-year 2026 WAKIX revenue guidance of $1.0–1.04 billion was reiterated.
Key Events · Executive and Board Changes · HRMY
-
CEO Succession Announced
Effective January 1, 2027, COO Peter Anastasiou will take over as President and CEO, succeeding Jeffrey Dayno, M.D., who retires December 31, 2026 and will serve as non-executive advisor through 2027.
-
Board Appointment
Anastasiou will also join the board as a Class I director effective January 1, 2027, filling the vacancy from Dayno's resignation, with his term expiring at the 2027 Annual Meeting.
-
2026 Guidance Reiterated
Full-year 2026 WAKIX net revenue guidance of $1.0 billion to $1.04 billion was reaffirmed, consistent with record Q2 2026 revenue of $261.3 million.
-
Pipeline Milestone Confirmed
The company remains on track to report multiple ascending dose (MAD) study data for BP-205 in Q4 2026.
Analysis · HRMY · Life Sciences
The planned CEO transition at Harmony Biosciences is now formalized, with COO Peter Anastasiou set to succeed Jeffrey Dayno effective January 1, 2027. Full-year 2026 WAKIX revenue guidance of $1.0–1.04 billion was also reaffirmed, and the Q4 2026 BP-205 MAD data readout remains on schedule. Coming after a CFO departure in July and amid record revenue, the move suggests the board is positioning for the next growth phase rather than reacting to distress.
How filings like this one have moved
In the 30 days to Oct 13, 2026, 29.1% of the 1502 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.50%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, HRMY was trading at $38.40 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.2B. The 52-week trading range was $25.52 to $43.49. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.